Procedures for UK paediatric investigation plan (PIPs)

AI Summary

This guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) outlines the requirements for Paediatric Investigation Plans (PIPs), waivers, and compliance checks under the Human Medicines Regulations 2012. A significant update involves the Windsor Framework, effective January 1, 2025, which categorizes medicines into 'Category 1' (UK-wide) and 'Category 2' to streamline licensing across the United Kingdom. Applicants must submit a PIP early in the drug development process, specifically upon the completion of human pharmacokinetic studies and before applying for marketing authorization. All submissions, including modifications and waivers, must be made through the digital MHRA portal; email applications are strictly prohibited. Key issues addressed include the necessity of a formal compliance check, which should be requested at least two months prior to a regulatory submission to avoid validation delays. While the MHRA acknowledges decisions from international regulators, it prioritizes UK-specific public health needs and unmet therapeutic requirements. To remain compliant, companies must ensure all relevant MHRA decision documents and compliance reports are included in their marketing applications, as international agreements alone are insufficient for UK validation.